• Chien-Hua Huang, Chiung-Yuan Hsu, Min-Shan Tsai, Tzung-Dau Wang, Wei-Tien Chang, and Wen-Jone Chen.
• Department of Emergency Medicine, National Taiwan University Hospital Yun-Lin Branch, Taiwan, ROC.
• Crit. Care Med. 2008 Nov 1; 36 (11 Suppl): S467-73.

ObjectiveErythropoietin has been noted for its cardioprotective effects. The objective of the study is to investigate its effects on postresuscitation myocardial dysfunction and therapeutic windows.DesignRandomized animal study.SettingAnimal research laboratory.SubjectsAdult male adult Wistar rats.InterventionsCardiopulmonary resuscitation was started after 6.5 or 9.5 mins of asphyxia-induced cardiac arrest. The resuscitated animals received either erythropoietin (1000, 3000, or 5000 U/kg) or placebo intravenously 3 mins after return of spontaneous circulation.Measurements And Main ResultsErythropoietin treatment improved the 3-day survival and left ventricular dP/dt40 and peak negative dP/dt after 6.5 mins asphyxia-induced cardiac arrest. The cardioprotective effects of erythropoietin decreased after 9.5 mins asphyxia-induced cardiac arrest with worse postresuscitation left ventricular dP/dt40 and peak negative dP/dt (p < .01 for both). The erythropoietin showed a dose-dependent response for its cardioprotective effects. The 3-day survival rates were higher in the group treated with erythropoietin 5000 U/kg than with 3000 and 1000 U/kg groups (p = .045 and .003, respectively). Postresuscitation left ventricular dP/dt40 and peak negative dP/dt were more preserved in the group treated with erythropoietin 5000 U/kg than the groups with lower doses (p < .05 for both).ConclusionsErythropoietin has the potential to improve postresuscitation myocardial dysfunction and short-term survival in appropriate therapeutic windows.

28 keywords...

hide…